Product Registration - The company has received medical device registration certificates for four products from the National Medical Products Administration [1] - Two of the approved respiratory "small joint inspection" products offer high sensitivity, specificity, and ease of operation, providing reports in as fast as 30 minutes [1] - The "small joint inspection" series has now expanded to 10 products, enhancing the company's "6/3+X respiratory infection nucleic acid rapid detection" system [1] Clinical Impact - The approved respiratory products are crucial for early identification of pathogens in respiratory infections, which is vital for precise medication and reducing antibiotic resistance [1] - The EB virus nucleic acid detection kit has undergone significant technical upgrades, improving detection sensitivity and supporting various specimen types [2] - The CYP3A5 gene polymorphism nucleic acid detection kit is the ninth product in the company's drug genome series, aimed at optimizing clinical medication plans for transplant patients [2]

Important Events - Changan Automobile plans to conduct L3-level autonomous driving pilot applications in collaboration with Changan Car Union Technology by Q1 2026 [1] - Huachangda has signed a strategic cooperation framework agreement with Shanghai Jiao Tong University Intelligent Manufacturing Research Institute and Shanghai Intelligent Manufacturing Functional Platform Company to jointly develop embodied intelligence and humanoid robots [1] - Qichuang Data intends to invest no more than 9 billion yuan to purchase servers primarily for providing cloud computing services to clients [1] - Zhongke Shuguang's single cabinet-level 640-card super node scaleX640 can be combined with dual scaleX640 super nodes to form a thousand-card-level computing unit [1] - Four-dimensional Map New has invested in Jianzhih Robot, becoming its largest shareholder, with the restructured "New Jianzhih" set to become the intelligent driving business platform [1] - Huabao New Energy has completed the functional prototype of the world's first light-charging Mars robot 5000 [1] - Yongding Co., Ltd. has achieved mass production of single-kilometer REBCO superconducting tape in the HF1200 series [1] - Hualing Cable, which has seen four consecutive trading limit increases, plans to acquire 70% of San Zhu Technology to integrate key technology segments of "cables" and "connectors" [1] - Jiangbolong forecasts a price increase of 30% to 35% for LPDDR4X/5X in Q1 2026 [1] - Shengxiang Biological has obtained medical device registration certificates for four products [1] - Dalian Technology's automotive connectors are compatible with L3-level intelligent driving scenarios [1] Investment and Operations - Yake Technology is currently validating some of its photoresist products with clients [1] - China Energy Construction has launched the first phase of the world's largest green hydrogen-ammonia integrated project [1] - Caixun Co., Ltd. plans to jointly invest in a fund specifically for a humanoid robot company [1] - Jingjia Microelectronics' CH37 series can provide a peak computing capability of 64 TOPS@INT8 [1] - Zhongbei Communication has exceeded a computing power scale of 17,000 P [1] - China General Nuclear Power has commenced full construction of the Ningde Unit 6 [1] - Huazhu High-Tech's 3D printing equipment is widely used in the aerospace sector [1] - Lianhua Holdings' subsidiary plans to invest 200 million yuan to purchase 4,000 accelerator cards and services for intelligent computing business [1] - Saiwei Electronics' Chip East can provide a complete set of mature process lithography machine reconstruction, new lithography machine installation and debugging, and high-quality spare parts supply services [1] - AVIC Chengfei plans to build a space equipment assembly base to lay the foundation for the production tasks of the "Haolong" cargo spacecraft [1] Contracts and Cooperation - Qichuang Data has signed a strategic cooperation framework agreement with Guangwei Technology and Guangjia Technology to quickly enter the optical chip and optical module industry [1] - Shengyang Technology's subsidiary FTA has signed a cooperation agreement for a South American project with the world's largest satellite company [1] - Mengsheng Electronics' satellite navigation products have been successfully applied to various launch vehicles including "Zhuque," "Changzheng," "Gushenxing," and "Kuaizhou" [1]

今日焦点 协创数据：拟斥资不超过90亿元采购服务器，主要用于为客户提供云算力服务 协创数据公告称，公司拟向多家供应商采购服务器，并签署相关采购合同，采购合同总金额预计不超过 90亿元，公司购买服务器主要用于为客户提供云算力服务。此次交易不构成重大资产重组，亦不构成关 联交易。公司已通过第四届董事会第九次会议审议通过该议案，尚需提交股东会审议。交易对手方信息 因商业秘密及战略发展考虑不予披露。 华昌达：与上海交大智能制造研究院、上海智能制造功能平台公司签署战略合作框架协议开展具身智能 及人形机器人的联合研发等 华昌达公告称，公司近日与上海交通大学上海智能制造研究院、上海智能制造功能平台有限公司签署 《战略合作框架协议》。三方同意在以下领域开展深度合作：融合具身智能及人形机器人的工业场景数 字化仿真技术与平台；针对机器人技术整体应用解决方案，开展技术转移与联合攻关；开展具身智能及 人形机器人的联合研发，大小脑、技能训练等技术的联合研究；特定用途具身及人形机器人的联合研制 和产业化应用。 航天工程：公司主营业务不涉及商业航天 航天工程发布股票交易异常波动公告称，公司的主营业务是以航天粉煤加压气化技术为核心，专业从事 ...

【重大事项】 中科电气：拟约70亿元投建年产30万吨锂离子电池负极材料一体化项目 中科电气(300035.SZ)公告称，公司与四川泸州（长江）经济开发区管理委员会签订投资协议，拟在四 川泸州（长江）经济开发区投资建设"年产30万吨锂离子电池负极材料一体化项目"，项目计划总投资约 人民币70亿元，分两期建设，一期项目建设年产20万吨锂离子电池负极材料一体化生产基地，计划投资 约47亿元；二期项目建设年产10万吨锂离子电池负极材料一体化生产基地，计划投资约23亿元。项目用 地约1500亩，建设周期为18个月。项目旨在扩大公司锂电负极业务规模，满足不断增长的锂电负极市场 需求，增强综合竞争力，但存在项目用地、审批、建设及市场环境等风险，预计短期内不会对公司业绩 产生重大影响。 今日晚间重要公告抢先看——中科电气拟约70亿元投建年产30万吨锂离子电池负极材料一体化项目；美 格智能发行境外上市股份获得中国证监会备案。 联合精密：拟1.94亿元收购迈特航空51%股权 联合精密(001268.SZ)公告称，公司拟以1.94亿元收购成都迈特航空制造有限公司51%股权。本次交易完 成后，迈特航空将成为公司控股子公司。迈特航空是 ...

智通财经APP讯，圣湘生物(688289.SH)发布公告，公司的四款产品于近日收到由国家药品监督管理局 颁发的《医疗器械注册证》，产品名称分别为：大肠埃希菌、鲍曼不动杆菌、嗜麦芽窄食单胞菌核酸检 测试剂盒(荧光PCR法);肺炎链球菌、流感嗜血杆菌、卡他莫拉菌核酸检测试剂盒(荧光PCR法);人 CYP3A5基因多态性核酸检测试剂盒(PCR-荧光探针法);EB病毒核酸检测试剂盒(荧光PCR法)。 ...

圣湘生物科技股份有限公司 关于自愿披露相关产品取得医疗器械注册证 的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者 重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 圣湘生物科技股份有限公司（以下简称"公司"或"圣湘生物"）的四款产品于近日 收到由国家药品监督管理局颁发的《医疗器械注册证》，现将相关情况公告如下： | 注册 | | | | | | | 注册 | 注册 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 人名 称 | | 注册证编号 | | | 产品名称 | 预期用途 | 类别 | 证有 效期 | | | | | | | 大肠埃希菌、鲍曼不 | 本试剂盒用于定性检测人痰液样 | | | | | 国 | 械 | 注 | 准 | 动杆菌、嗜麦芽窄食 | 本的大肠埃希菌、鲍曼不动杆菌、 | | | | | | 20253402567 | | | 单胞菌核酸检测试 | 嗜麦芽窄食单胞菌核酸。 | | | | | | | | | 剂盒（荧光 PCR 法） | | | | | 圣湘 | | | | ...

Core Viewpoint - The company has received medical device registration certificates from the National Medical Products Administration for four products, indicating regulatory approval and potential market entry [1] Group 1: Product Details - Two respiratory "small joint inspection" products have high sensitivity, high specificity, and ease of operation, capable of providing results in as fast as 30 minutes [1] - The products target major pathogens responsible for community-acquired pneumonia and pediatric respiratory infections, including Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis [1] - The company has upgraded its EB virus nucleic acid detection kit, enhancing detection sensitivity and supporting various specimen types such as plasma and whole blood [1] - The CYP3A5 gene polymorphism nucleic acid detection kit is designed to guide clinical medication plans for the core anti-rejection drug tacrolimus post-transplant [1]

新华财经上海12月16日电 在制度创新赋能、监管机制优化、服务体系升级的多重利好驱动下，科创板 并购重组市场正释放前所未有的生机与活力。记者获悉，自"科八条"发布以来，科创板上市公司累计新 披露并购交易156单，已有近110单并购交易顺利完成。 上交所统计数据显示，自2024年6月"科八条"发布以来，科创板新披露的156单并购交易中，发股／可转 债类交易40单、现金重大类交易9单。尤其是，2025年以来市场热度持续升温，新增披露并购交易95 单，含发股／可转债类29单、现金重大类7单，两项数据均较上年同期显著提升。 从重大资产重组维度看，2024年全年发布17单交易，已追平2019年至2023年五年合计数；2025年至今发 布交易已达36单，远超2024年全年水平，并超过2019至2024年六年总和，增长势头迅猛。 "科八条"实施以来，已有近110单并购交易顺利完成，整体完成率达七成，另有20余单正积极推进。从 交易结构看，现金非重大交易由于金额较小、程序简单，实施周期更短；同时，多单发行股份购买资产 或现金重大交易也取得实质性进展。 随着多个"首单"创新案例接连落地，资本市场制度的包容性与适应性得到充分彰显 ...

近期部分重组交易宣告终止，尤以半导体行业并购终止案例较多。这些终止交易的多为中小民营上市公 司，以发行股份或现金重大类交易为主，终止的核心症结集中于交易双方未能就关键条款达成一致。 不过，近期部分重组交易宣告终止，尤以半导体行业并购终止案例较多。这些终止交易的多为中小民营 上市公司，以发行股份或现金重大类交易为主，终止的核心症结集中于交易双方未能就关键条款达成一 致。 自2024年6月"科八条"发布以来，科创板上市公司累计新披露并购交易156单，其中2025年以来新增披露 并购交易95单。已有近110单并购交易顺利完成，整体完成率达七成，另有20余单正在推进中。 "科八条"发布以来，科创板并购重组热度持续提升，目前已有七成公司完成交易，但近期频现重组交易 终止现象，引发市场关注。 有半导体行业人士分析称，近期该行业并购终止案例较多，存在两方面客观原因：一方面，行业并购活 跃度高、披露案例基数大，相应终止案例数量相应随之增加；另一方面，国内半导体产业近年发展迅 速，一级市场关注度与估值水平较高，叠加部分标的公司股东结构复杂、利益诉求多元，也会增加上市 公司并购的谈判难度。同时，行业需求波动与市场环境变化，也促使 ...

Core Insights - The article promotes the "Medical Engineering Innovation and Transformation Workshop" organized by Shanghai Jiao Tong University, aimed at fostering collaboration between doctors, engineers, and investors to address challenges in medical device innovation [2][4][23] Course Highlights - The workshop offers a unique opportunity for participants to engage in innovative thinking and explore collaboration in medical technology innovation [4] - It emphasizes the integration of medical needs with engineering solutions to create innovative medical products and facilitate their transformation into market-ready solutions [4][5] - Participants will learn the Biodesign innovation methodology, which is a global leading model for efficient transformation in medical engineering [5] Training Information - The workshop is scheduled for January 10-11, 2026, with a group price of 2500 yuan per person [6] - It includes practical training over one and a half days, focusing on the core methods and elements of medical engineering innovation and transformation [7][9] Target Audience - The workshop is suitable for various professionals, including doctors, engineering technicians, manufacturers, distributors, and investors interested in medical device innovation [9] Course Structure - The course includes sessions on medical technology innovation, intellectual property management, and practical exercises to foster interdisciplinary collaboration [10][12][15] - Participants will engage in group discussions to identify and analyze real medical industry pain points and explore potential innovative solutions [15] Expert Faculty - The workshop features a team of distinguished experts from Shanghai Jiao Tong University and the biomedical engineering field, with extensive experience in medical technology and investment [17][20] Certification - Upon completion, participants will receive a certificate from Shanghai Jiao Tong University School of Medicine and continuing medical education credits [23]